{Reference Type}: Journal Article
{Title}: Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx.
{Author}: Hauswald H;Jensen AD;Krauss J;Haselmann R;Lossner K;Hartmann S;Windemuth-Kieselbach C;Münter MW;Debus J;
{Journal}: Clin Transl Radiat Oncol
{Volume}: 13
{Issue}: 0
{Year}: Nov 2018
{Factor}: 4.739
{DOI}: 10.1016/j.ctro.2018.09.005
{Abstract}: <B>OBJECTIVE: </B>This phase II trial was designed to evaluate efficacy and safety of a highly intensified therapy in locally advanced squamous cell carcinoma of the oro-, hypopharynx and larynx.<BR><B>METHODS: </B>In this prospective, mono-centric, open-label, non-randomized phase II trial the single treatment arm consisted of a combined induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, followed by bioradiation with the monoclonal antibody cetuximab, carbon ion boost (24Gy(RBE) in 8 fractions) and IMRT (50 Gy in 25 fractions). The trial was closed early due to slow accrual.<BR><B>RESULTS: </B>Eight patients (median age 52.5 years) were enrolled into the trial. The median follow-up was 13 months and the 12-months locoregional tumor control, progression-free survival and overall survival rates were 100.0% each. Complete remission was achieved in 7 patients. The most commonly late radiation adverse event was xerostomia (85.7% at 12 months). Five serious adverse events with recovery were documented in 4 patients: mucositis grade 3 (n = 2), decreased lymphocyte count grade 4, febrile neutropenia grade 4 and hypersensitivity grade 3 to cetuximab (n = 1 each). Most symptom scales had their worst value at the last treatment day and recovered until the 4th follow-up visit.<BR><B>CONCLUSIONS: </B>The study treatment was tolerable and promising. Reduced quality of life recovered for most aspects until the last follow-up visit.